06-413 | Anti-NFκB p52 Antibody

100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HIP, WBRbPurifiedPolyclonal Antibody
      Catalogue Number06-413
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-NFκB p52 Antibody
      Background InformationThe NFκB transcription factor was originally identified as a protein complex consisting of a 65 kDa DNA binding subunit and an associated 50 kDa protein. The 65 kDa subunit is functionally related to c-Rel p75 and Rel B p68. The p50 subunit was initially believed to be a functionally unique protein derived from the amino terminus of a precursor designated p105. A cDNA has been isolated that encodes an alternative DNA binding subunit of NFκB. It is synthesized as a 100 kDa protein that is expressed in a variety of cell types and, like p105, undergoes cleavage to generate its NFκB subunit, in this case a protein designated p52 (previously referred to as p49). In contrast to p50 derived from p105, p52 acts in synergy with p65 to stimulate the HIV enhancer in transiently transfected Jurkat cells.
      Product Information
      • Raji cell lysate, Jurkat whole cell lysate
      PresentationProtein A Purified immunoglobulin in in 0.1M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% NaN3 as a preservative.
      ApplicationDetect NFκB p52 with Anti-NFκB p52 Antibody (Rabbit Polyclonal Antibody), that has been shown to work in IP & WB.
      Key Applications
      • Immunoprecipitation
      • Western Blotting
      Biological Information
      ImmunogenKLH conjugated synthetic peptide (CYNPGLDGIIEYDDFK) contained within amino acids 4-19 of human NF κB, p52
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityRecognizes NFκB p52 and its precursor.
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryNFKB has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NFKB is activated by a wide variety of stimuli such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth. For reviews, see Chen et al. (1999) [PubMed 9895331] and Baldwin (1996) [PubMed 8717528].[supplied by OMIM]
      Gene Symbol
      • NFKB2
      • LYT10
      • LYT-10
      • H2TF1
      • Lyt10
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: Q00653 # Appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
      SIZE: 900 amino acids; 96749 Da
      SUBUNIT: Active NF-kappa-B is a heterodimer of an about 52 kDa DNA-binding subunit and the weak DNA-binding subunit p65. Two heterodimers might form a labile tetramer.
      SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
      DOMAIN: SwissProt: Q00653 The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation (By similarity). & The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
      PTM: While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing. & Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing. & Constitutive processing is tightly suppressed by its C- terminal processing inhibitory domain, named PID, which contains the death domain.
      DISEASE: SwissProt: Q00653 # A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant. & A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT). & In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
      SIMILARITY: Contains 7 ANK repeats. & Contains 1 death domain. & Contains 1 RHD (Rel-like) domain.
      Molecular Weight52 kDa, and precursor (100 kDa)
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by immunoblot on RIPA lysates from Raji cells
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-NFkB, p52 - 2037637 2037637
      Anti-NFkB, p52 - 2073777 2073777
      Anti-NFkB, p52 - DAM1650327 DAM1650327
      Anti-NFkB, p52 - DAM1690646 DAM1690646
      Anti-NFkB, p52 - DAM1749927 DAM1749927
      Anti-NFkB, p52 - DAM1794301 DAM1794301
      Anti-NFkB, p52 - DAM1821107 DAM1821107
      Anti-NFkB, p52 - JBC1863303 JBC1863303
      Anti-NFkB, p52 - NG1554361 NG1554361
      Anti-NFkB, p52 Polyclonal Antibody 2905311


      Reference overviewApplicationPub Med ID
      B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.
      Fei, F; Joo, EJ; Tarighat, SS; Schiffer, I; Paz, H; Fabbri, M; Abdel-Azim, H; Groffen, J; Heisterkamp, N
      Oncotarget  6  11378-94  2015

      Show Abstract
      25869099 25869099
      NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression.
      Uno, M; Saitoh, Y; Mochida, K; Tsuruyama, E; Kiyono, T; Imoto, I; Inazawa, J; Yuasa, Y; Kubota, T; Yamaoka, S
      PloS one  9  e88347  2014

      Show Abstract
      Western Blotting24533079 24533079
      Maspin expression is regulated by the non- canonical NF-κB subunit in androgen-insensitive prostate cancer cell lines.
      Guo F, Kang S, Zhou P, Guo L, Ma L, Hou J
      Molecular immunology  49  8-17.  2011

      Show Abstract
      21856005 21856005
      Beyond the enhanceosome: cluster of novel κB sites downstream of the human IFN-β gene is essential for lipopolysaccharide-induced gene activation.
      Goh, FG; Thomson, SJ; Krausgruber, T; Lanfrancotti, A; Copley, RR; Udalova, IA
      Blood  116  5580-8  2010

      Show Abstract
      Western Blotting20855868 20855868
      Loss of Negative Feedback Control of Nuclear Factor-{kappa}B2 Activity in Lymphocytes Leads to Fatal Lung Inflammation.
      Yang L, Cui H, Wang Z, Zhang B, Ding J, Liu L, Ding HF
      Am J Pathol  2010

      Show Abstract
      20363924 20363924
      GSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells.
      Graham, JR; Tullai, JW; Cooper, GM
      The Journal of biological chemistry  285  4472-80  2010

      Show Abstract
      20018891 20018891
      Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors.
      Terragni, J; Graham, JR; Adams, KW; Schaffer, ME; Tullai, JW; Cooper, GM
      BMC cell biology  9  6  2008

      Show Abstract
      Western Blotting18226221 18226221
      Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.
      Wang, Z; Zhang, B; Yang, L; Ding, J; Ding, HF
      The Journal of biological chemistry  283  10698-706  2008

      Show Abstract
      18281283 18281283
      Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
      Yang, DT; Young, KH; Kahl, BS; Markovina, S; Miyamoto, S
      Molecular cancer  7  40  2008

      Show Abstract
      18489772 18489772
      Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
      Markovina, S; Callander, NS; O'Connor, SL; Kim, J; Werndli, JE; Raschko, M; Leith, CP; Kahl, BS; Kim, K; Miyamoto, S
      Molecular cancer research : MCR  6  1356-64  2008

      Show Abstract
      18708367 18708367


      Pathways and Biomarkers of Toll-like Receptor (TLR) Signaling
      Western Blotting Tools

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      05-361 Anti-NFκB p52 Antibody Show Pricing & Availability
      07-1829 Anti-phospho-NF-kB (p100) (Ser707) Antibody Show Pricing & Availability
      ABS1515 Anti-phospho NFkB p52, (Ser222) Antibody Show Pricing & Availability


      Life Science Research > Antibodies and Assays > Primary Antibodies